SPPAM
BHVN

Summit Partners Public Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Summit Partners Public Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-160,000
Closed -$7.01M – 151
2019
Q2 		$7.01M Buy
+160,000
New +$9.02M 0.7% 63

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Summit Partners Public Asset Management's BHVN Position: Q3 2019 in Review

Summit Partners Public Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2019, closing a stake of 160,000 shares — an estimated $7.01M sold.

Summit Partners Public Asset Management first reported a position in BHVN in Q2 2019 and held it in 1 quarter. The position peaked at $7.01M in Q2 2019. 184 funds tracked by Wall St. Rank hold BHVN as of Q3 2019.

  • Summit Partners Public Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2019 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 160,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2019, an estimated $7.01M.
  • Summit Partners Public Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 1 quarter.
  • Summit Partners Public Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $7.01M in Q2 2019.
  • 184 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2019.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.